Glossary
Duplicate Ingredient Risk
Updated February 22, 2026
Duplicate ingredient risk appears when the same active or equivalent source is counted more than once across products.
Why it matters
Duplicate counting can shift both exposure and side-effect risk without obvious label cues.
Duplicate detection examples
- Naming drift: vitamin D3 in multiple product names.
- Synonym drift: ascorbate and buffered vitamin C variants.
- Country and abbreviation drift: magnesium citrate variants and similar salts.
How to catch hidden duplicates
- Proprietary blends that hide standardized actives.
- Multi-ingredient products that include overlapping compounds.
Action ladder
- reduce one source first and hold 24–72 hours,
- monitor for symptom separation,
- if improved, reintroduce only one source for one test period.
This avoids over-attribution and improves follow-up clarity.
How Unfair uses it
Unfair flags overlaps and suggests de-overlap review before adding additional actives.
Cross-site references
Uncertainty
- Evidence is limited for duplicate impact in all proprietary blends.
- Evidence is limited on duplicate effects when half-life overlap differs between forms.
How this appears in Unfair
Unfair highlights overlap clusters and prioritizes safer reconfiguration suggestions.
Clinical safety note
If duplicate reduction does not settle symptoms, pause overlap and request clinician review before restarting.